| Pharmaceutical Information |
| Drug Name |
Selinexor |
| Drug ID |
BADD_D02493 |
| Description |
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. It is currently approved for the treatment of multiple myeloma, a cancer which forms from antibody-producing plasma cells.[L7117,L7120] This condition is typically treated with high dose [bortezomib] and dexamethasone chemotherapy followed by autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant.[L7123] Selinexor was approved by the FDA in June 2019. It was granted fast track and orphan designation as well as accelerated approval based on single arm, open label trial data. The Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) trial is planned to finish in 2020.[L7126] |
| Indications and Usage |
Not Available |
| Marketing Status |
Not Available |
| ATC Code |
L01XX66 |
| DrugBank ID |
DB11942
|
| KEGG ID |
D11222
|
| MeSH ID |
C585161
|
| PubChem ID |
71481097
|
| TTD Drug ID |
D00LNW
|
| NDC Product Code |
11014-0454; 11014-0455; 72237-103; 72237-101; 72237-102; 11014-0393; 11014-0456; 72237-104; 62009-1911 |
| Synonyms |
selinexor | Xpovio | KPT-330 |
|
| Chemical Information |
| Molecular Formula |
C17H11F6N7O |
| CAS Registry Number |
1393477-72-9 |
| SMILES |
C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
